Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms (Q38430909)

3 September 2017

1 reference

title

Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

3 September 2017

1 reference

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Melania Gaggini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Amalia Gastaldelli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Chiara Saponaro

1

1 reference

3 September 2017

Melania Gaggini

2

1 reference

3 September 2017

Amalia Gastaldelli

3

1 reference

3 September 2017

1 June 2015

1 reference

3 September 2017

Current diabetes report

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

607

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25894944%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11892-015-0607-4

9 June 2020

exact match

0 references

cites work

IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Liver transplantation and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Why does NAFLD predict type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The metabolically benign and malignant fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Nonalcoholic fatty liver disease in lean individuals in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Adipose tissue insulin resistance in adolescents with and without type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Genetic control of de novo lipogenesis: role in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Obesity, insulin resistance and free fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Dose-response effect of elevated plasma free fatty acid on insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

21 January 2018

The genetics of NAFLD.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Genomic aspects of NAFLD pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Association study of IRS1 gene polymorphisms with type 2 diabetes in south Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Benefits of lifestyle modification in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Sugar, uric acid, and the etiology of diabetes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Non-alcoholic steatohepatitis: a microbiota-driven disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The paradox of progress: environmental disruption of metabolism and the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Effects of endocrine disruptors on obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Serum concentrations of phthalate metabolites are related to abdominal fat distribution two years later in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

PPAR-mediated activity of phthalates: A link to the obesity epidemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The many faces of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes results from the National Health and Examination Survey 1999-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Persistent organic pollutant exposure leads to insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Non-invasive markers for hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Can NASH be diagnosed, graded, and staged noninvasively?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

A simple index of lipid overaccumulation is a good marker of liver steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Comparison of blood tests for liver fibrosis specific or not to NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Oxidized LDL and the Risk of Coronary Heart Disease: Results from the MONICA/KORA Augsburg Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0607-4

Impact of environmental endocrine disrupting chemicals on the development of obesity

21 January 2018

1 reference

12 December 2020

ARFI cut-off values and significance of standard deviation for liver fibrosis staging in patients with chronic liver disease

1 reference

12 December 2020

Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle

1 reference

12 December 2020

Fatty liver and lipotoxicity

1 reference

12 December 2020

Effects of binge ethanol on lipid homeostasis and oxidative stress in a rat model of nonalcoholic fatty liver disease.

1 reference

12 December 2020

Introduction of fast MR imaging in the assessment of hepatic steatosis

1 reference

12 December 2020

Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment?

1 reference

12 December 2020

Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data.

1 reference

12 December 2020

Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes

1 reference

12 December 2020

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects

1 reference

12 December 2020

1 reference

12 December 2020

Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up

1 reference

12 December 2020

Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI)

1 reference

12 December 2020

Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease

1 reference

12 December 2020

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

1 reference

12 December 2020

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

1 reference

12 December 2020